文献速递垂体与肾上腺疾病

左酮康唑治疗内源性库欣综合征的3期SONICS试验

Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial.
PubMed 文献 · Lancet Diabetes Endocrinol · 2019-09-18

SONICS是一项3期、多中心、开放标签、单臂试验,纳入94例内源性库欣综合征患者,评估左酮康唑的疗效与安全性。常见不良事件为恶心和头痛,部分患者出现肝酶升高、QT间期延长和可疑肾上腺功能不全。

要点

  • 左酮康唑可使部分库欣综合征患者mUFC持续正常化,31%达到主要终点。
  • 需监测肝毒性、QT间期延长和肾上腺功能不全等不良事件。
  • 常见不良事件为恶心(32%)和头痛(28%),13%因不良事件停药。

核心结论

  • 每日两次口服左酮康唑可带来尿游离皮质醇的持续改善,安全性和耐受性可接受,可能成为库欣综合征药物治疗的有用选择。

研究设计与样本

  • 治疗方案包括2-21周剂量递增期(起始150 mg每日两次,每次增加150 mg直至mUFC正常化,最大600 mg每日两次)和6个月维持期。

主要发现

  • 进入维持期的77例患者中,62例(81%)在剂量滴定结束时mUFC正常化。
  • 最常见不良事件为恶心(30例[32%])和头痛(26例[28%]);12例(13%)因不良事件停药。

关键数值与推荐

  • 主要终点为维持期结束时mUFC正常化且维持期未增加剂量的患者比例(意向治疗人群)。
  • 预设特别关注的不良事件为潜在肝毒性、校正QT间期延长和肾上腺功能不全。

临床怎么用

  • 左酮康唑可用于内源性库欣综合征的药物治疗,但需在治疗期间监测肝功能、QT间期和肾上腺功能。
  • 剂量应从150 mg每日两次起始,根据mUFC逐渐滴定至最大600 mg每日两次。

局限性

  • 本研究为单臂、开放标签设计,无对照组。
  • 样本量有限(94例),且多数为垂体性库欣综合征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Levoketoconazole is a ketoconazole stereoisomer in development for treatment of Cushing's syndrome and has not been assessed previously in a clinical trial in patients with Cushing's syndrome. We aimed to investigate the efficacy and safety of levoketoconazole in patients with endogenous Cushing's syndrome. METHODS: SONICS is a phase 3, multicentre, open-label, non-randomised, single-arm study in which we recruited adults (≥18 years) with confirmed Cushing's syndrome and a mean 24-h urinary free cortisol (mUFC) of at least 1·5 times the upper limit of normal from 60 hospital and community sites in 19 countries (15 countries in Europe, and Canada, Israel, Turkey, and the USA). Patients were treated with oral levoketoconazole in a 2-21 week incremental dose-titration phase starting at 150 mg twice daily (150 mg increments until mUFC normalisation, maximum 600 mg twice daily) and a 6-month maintenance phase. The primary outcome was the proportion of patients with mUFC normalisation at end of maintenance, without dose increase during the maintenance phase (in the intention-to-treat population). Prespecified adverse events of special interest were potential liver toxicity, corrected QT prolongation, and adrenal insufficiency. This trial is registered with ClinicalTrials.gov, NCT01838551. FINDINGS: Between July 30, 2014, and June 30, 2017, 201 individuals were screened and 94 patients were enrolled and received at least one dose of study medication. Of the 94 patients, 80 (85%) had pituitary Cushing's syndrome. Mean mUFC at baseline was 671·4 nmol/24 h (243·3 μg/24 h), which is 4·9 times the upper limit of normal. Of the 77 patients who advanced to the maintenance phase, 62 (81%) had mUFC normalisation by end-of-dose titration. At the end of the 6-month maintenance phase, 29 (31%) of 94 patients were responders; the least-squares mean estimate of the proportion of responders was 0·30 (95% CI 0·21-0·40; p=0·0154 vs null hypothesis of ≤0·20). The most common adverse events in the 94 patients were nausea (30 [32%]) and headache (26 [28%]). Adverse events led to study discontinuation in 12 (13%) of 94 patients. Two patients had a QT interval (Fridericia corrected) of more than 500 ms, and three patients had suspected adrenal insufficiency. Alanine aminotransferase reversibly increased to more than three times the upper limit of normal in ten (11%) patients. Four patients had serious adverse events that were considered probably or definitely related to the study drug: abnormal liver function test results (n=1), prolonged QT interval (n=2), and adrenal insufficiency (n=1). One person died from colon carcinoma unrelated to study medication. INTERPRETATION: Twice-daily oral levoketoconazole treatment led to sustained improvements in urinary free cortisol, with an acceptable safety and tolerability profile. Levoketoconazole might represent a useful therapeutic option for the medical treatment of Cushing's syndrome. FUNDING: Strongbridge Biopharma.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Fleseriu M, Pivonello R, Elenkova A, et al. Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial. Lancet Diabetes Endocrinol. 2019. PMID: 31542384. doi:10.1016/S2213-8587(19)30313-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。